Qiagen N.V. (NYSE:QGEN) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Qiagen N.V. (NYSE:QGEN) have earned an average rating of “Moderate Buy” from the twelve brokerages that are covering the company, MarketBeat Ratings reports. Seven equities research analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among brokerages that have covered the stock in the last year is $44.9789.

QGEN has been the subject of several recent analyst reports. Zacks Research upgraded shares of Qiagen from a “strong sell” rating to a “hold” rating in a research note on Wednesday, April 29th. Robert W. Baird set a $43.00 target price on shares of Qiagen and gave the company an “outperform” rating in a research note on Wednesday, April 29th. JPMorgan Chase & Co. cut their target price on shares of Qiagen from $60.00 to $45.00 and set an “overweight” rating for the company in a research note on Wednesday, April 29th. UBS Group set a $52.00 target price on shares of Qiagen in a research note on Monday, February 9th. Finally, Weiss Ratings downgraded shares of Qiagen from a “hold (c)” rating to a “hold (c-)” rating in a research note on Tuesday, May 12th.

Qiagen News Summary

Here are the key news stories impacting Qiagen this week:

• Positive Sentiment: QIAGEN announced two custom RUO digital PCR assays to support research and surveillance efforts tied to the Bundibugyo ebolavirus outbreak, reinforcing demand for its QIAcuity digital PCR platform and its role in infectious-disease monitoring. Article Title
• Positive Sentiment: A Zacks commentary pointed to longer-term growth drivers for QIAGEN, including new product launches, automation via Connect, and expansion of the QIAstat-Dx menu, suggesting the company is working to stabilize growth through 2027. Article Title
• Neutral Sentiment: Qiagen’s second-quarter and multi-year earnings estimates were trimmed by Zacks Research, but the firm kept a Hold rating and still sees earnings growth over the next several years. Article Title
• Neutral Sentiment: Pomerantz LLP said it is investigating claims on behalf of Qiagen investors, which adds legal uncertainty but does not yet indicate a formal lawsuit or financial impact. Article Title
• Negative Sentiment: Multiple Zacks Research updates lowered earnings forecasts for FY2026, FY2027, FY2028 and several quarterly periods, signaling some concern about near-term profitability and tempering enthusiasm for the stock. Article Title

Qiagen Price Performance

Shares of NYSE QGEN opened at $36.65 on Friday. The stock has a market capitalization of $7.55 billion, a price-to-earnings ratio of 19.14, a PEG ratio of 3.59 and a beta of 0.64. The business has a 50-day moving average of $37.76 and a 200-day moving average of $44.80. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.21 and a quick ratio of 2.57. Qiagen has a fifty-two week low of $32.53 and a fifty-two week high of $57.81.

Qiagen (NYSE:QGEN) last announced its quarterly earnings data on Thursday, May 7th. The company reported $0.54 earnings per share for the quarter, meeting the consensus estimate of $0.54. Qiagen had a return on equity of 14.40% and a net margin of 19.16%.The company had revenue of $492.32 million during the quarter, compared to analysts’ expectations of $496.15 million. During the same quarter last year, the company earned $0.56 EPS. As a group, sell-side analysts predict that Qiagen will post 2.43 earnings per share for the current fiscal year.

Qiagen Increases Dividend

The business also recently disclosed an annual dividend, which will be paid on Tuesday, July 14th. Shareholders of record on Tuesday, July 7th will be issued a $0.35 dividend. This is an increase from Qiagen’s previous annual dividend of $0.26. This represents a dividend yield of 104.0%. The ex-dividend date is Tuesday, July 7th. Qiagen’s dividend payout ratio is presently 13.61%.

Hedge Funds Weigh In On Qiagen

Several institutional investors and hedge funds have recently modified their holdings of QGEN. Lingohr Asset Management GmbH acquired a new stake in Qiagen during the third quarter worth approximately $4,218,000. Allianz Asset Management GmbH lifted its position in Qiagen by 53.7% during the third quarter. Allianz Asset Management GmbH now owns 1,529,224 shares of the company’s stock worth $68,028,000 after acquiring an additional 534,527 shares during the last quarter. Retirement Systems of Alabama acquired a new stake in Qiagen during the third quarter worth approximately $2,868,000. Barclays PLC lifted its position in Qiagen by 14.3% during the third quarter. Barclays PLC now owns 1,086,931 shares of the company’s stock worth $48,564,000 after acquiring an additional 135,638 shares during the last quarter. Finally, Great Lakes Advisors LLC acquired a new stake in Qiagen during the third quarter worth approximately $3,677,000. 70.00% of the stock is currently owned by institutional investors and hedge funds.

About Qiagen

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.